While directly targeting transcription factors like NEUROD1, which mediate transcriptional and epigenetic changes, remains challenging, an interesting study showed that a small molecular inhibitor targeting the transcription factor ONECUT2—whose expression is linked to poor clinical outcomes—effectively reduced tumor volume and proliferation in a mouse model (Rotinen et al., 2018). Here, NEUROD1 is linked to neoplasm.